Salarius Pharmaceuticals Inc.
13F holders, Q4 2024 (December 31)6holders −1
0new positions
2sold out
$1.84avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding Salarius Pharmaceuticals Inc. in their 13F filings, down 1 from Q3 2024. 0 opened new positions and 2 sold out. The largest holders were UBS Group AG ($13K), Osaic Holdings, Inc. ($297) and Bank of America Corp. ($20).
- Company
- Salarius Pharmaceuticals Inc.
- CUSIP
- 79400X404
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $7K |
All 13F filers, Q3 2024 → Q4 2024: 6,821 shares bought and 4,806 shares sold, net +2,015 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | Add +2623.5% | 7,081 | $13K |
| Osaic Holdings, Inc. | 0.00% | No change | 162 | $297 |
| Bank of America Corp. | 0.00% | Reduce -38.9% | 11 | $20 |
| Morgan Stanley | 0.00% | No change | 7 | $13 |
| SBI Securities Co., Ltd. | 0.00% | — | 1 | $2 |
| BlackRock, Inc. | 0.00% | No change | 1 | $2 |
"% of holder's portfolio" is SALARIUS PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Salarius Pharmaceuticals Inc. the manager owns.